Medicine and Dentistry
Patient
100%
Therapeutic Procedure
75%
Overall Survival
42%
Gemcitabine
36%
Non Small Cell Lung Cancer
32%
Survival
29%
Neoplasm
23%
Cisplatin
22%
Skeletal Muscle
21%
Inpatient
18%
Isocitrate Dehydrogenase
17%
Immune Checkpoint Inhibitor
17%
Malignant Neoplasm
15%
Diagnosis
14%
Protein Intake
14%
Ganglioglioma
13%
Breast Cancer
12%
Odds Ratio
12%
Progression Free Survival
11%
Proportional Hazards Model
11%
Carboplatin
10%
Glioblastoma
10%
Neutrophil
10%
Pembrolizumab
9%
Male
9%
Lung Cancer
9%
Liver Metastasis
9%
Prognostic Factor
8%
Recurrence Free Survival
8%
Body Weight
7%
Follow up
7%
Sex
7%
Anticarcinogen
7%
Bone Metastasis
6%
Clinical Feature
6%
Patient with Cancer
6%
Toxicity
6%
Protein
6%
Epidermal Growth Factor Receptor
5%
Logistic Regression Analysis
5%
Cancer Staging
5%
Nutrient Intake
5%
Nutritional Support
5%
Macrophage
5%
Cervical Cancer
5%
Regression Analysis
5%
Age
5%
Nursing and Health Professions
Patient
51%
Gemcitabine
32%
Overall Survival
26%
Confidence Interval
20%
Cisplatin
19%
Inpatient
18%
Weight
14%
Body Composition
14%
Woman
14%
Non Small Cell Lung Cancer
13%
Breast Cancer
12%
Odds Ratio
12%
Malignant Neoplasm
10%
Malnutrition
9%
Lung Cancer
9%
Compliance
8%
Chemotherapy
8%
Carboplatin
8%
Progression Free Survival
7%
Survival
7%
Anticarcinogen
7%
Pembrolizumab
7%
Control
7%
Toxicity
6%
Quality of Life
6%
Dose
5%
Procedures
5%
Pharmacology, Toxicology and Pharmaceutical Science
Overall Survival
40%
Gemcitabine
36%
Immune Checkpoint Inhibitor
34%
Survival
27%
Non Small Cell Lung Cancer
22%
Cisplatin
22%
Neoplasm
15%
Glioma
13%
Randomized Controlled Trial
12%
Malignant Neoplasm
12%
Breast Cancer
12%
Progression Free Survival
11%
Carboplatin
10%
Glioblastoma
10%
Pembrolizumab
9%
Liver Metastasis
9%
Clinical Trial
8%
Anticarcinogen
7%
Bone Metastasis
6%
Comorbidity
6%
Clinical Feature
6%
Toxicity
6%
Epidermal Growth Factor Receptor
5%
